Careers  |  Sign In  |  Register

Evaluating the Role of Molecular Testing in Lung Cancer

Nathan A. Pennell, MD, PhD, director of the Lung Cancer Medical Oncology Program at Taussig Cancer Institute at the Cleveland Clinic, emphasizes the importance of molecular testing before establishing a lung cancer treatment plan, particularly for nonsquamous non-small cell lung cancer (NSCLC) patients. Dr. Pennell recommends delaying immunotherapy until molecular testing is complete, as patients with oncogenic driver mutations may experience significant toxicity upon switching to a more targeted immunotherapy.

Learn more by clicking here.